Investigators identified dozens of Alzheimer's-related epigenetic signatures based on cytosine methylation and other profiles in Alzheimer's-related cell lines and patient samples.
NanoView will develop custom antibody-based assays on its ExoView platform to identify EVs containing biomarkers potentially linked to the neurological disorders.
Of participants with high genetic risk, 1.13 percent with a favorable and 1.78 percent with an unfavorable lifestyle developed dementia over a median eight years.
Individuals with Alzheimer's disease are enriched for somatic mutations in brain tissue that affect tau-related pathways, as compared to unaffected individuals.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
